Orca-T Approval Validates Years of Graft Engineering Research

On June 30, 2026, the FDA approved allogeneic regulatory T cell–containing immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi; Orca-T) for adults with hematological malignancies, based on findings from the phase 3 Precision-T trial (NCT05316701).^1,2 The trial enrolled 187 patients with acute leukemias or myelodysplastic syndrome undergoing matched donor transplantation with a myeloablative regimen.

In an interview with CancerNetwork^®, Wendy Stock, MD, the Anjuli Seth Nayak Professor of Medicine, cochair of the Leukemia Committee for the National Cancer Institute–supported Alliance for Clinical Trials in Oncology, and coleader of the Clinical and Experimental Therapeutics Research Program at the University of Chicago Medicine Comprehensive Cancer Center, discussed what the approval validates conceptually about engineering the allograft itself. She also highlighted how it may reshape the way clinicians think about the graft as a modifiable product rather than something that is simply infused.

Transcript:

CancerNetwork: What does this approval validate conceptually? Does it change how clinicians should think about the allograft as a drug that can be engineered rather than just infused?

Stock: It does give us some validation of many years of work that has been ongoing to try to manipulate the graft in order to improve outcomes for patients undergoing allogeneic transplant, where the big risks are relapse and graft-versus-host disease, which sometimes go hand in hand because of the complications that occur after allogeneic transplant: the need for more immunosuppression, and then the increased risk of relapse.

I do think this is an important advance, along with other things that have been progressing in the world of allogeneic transplant, other manipulations that do not always have to do with graft engineering. But this shows and validates that graft engineering is possible, and is possible in a successful manner to improve outcomes for patients undergoing allogeneic transplant.

References

1. FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation for adults with hematologic malignancies. News release. FDA. June 30, 2026. Accessed July 8, 2026. https://tinyurl.com/38s3wznr
2. Meyer EH, Salhotra A, Gandhi AP, et al. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026;147(11):1168-1177. doi:10.1182/blood.2025031313